Search

Displaying results 2821 - 2830 of 10000 in total
  1. Drug

    Oxycodegol

    go.drugbank.com/drugs/DB14146
    Investigational

    Nektar Therapeutics has filed an application for FDA approval of Loxicodegol for use in the treatment of chronic lower back pain [L3263] … The lack of abuse potential is believed to be due to the drug's slow rate of entry into brain, a unique characteristic compared to others in the opioid class [A33997, A34016].

    Categories: Heterocyclic Compounds with 4 or More Rings
  2. Drug

    Romiplostim

    go.drugbank.com/drugs/DB05332
    ApprovedInvestigational

    FDA approved on August 22, 2008. … Each domain consists of 14 amino acids. Interestingly, romiplostim's amino acid sequence is not similar to that of endogenous thrombopoietin.

    Products: g/vial, ROMIPLATE 250 ug INJECTION
  3. Drug

    Thiabendazole

    go.drugbank.com/drugs/DB00730
    ApprovedVet approvedWithdrawn

    It is active against a variety of nematodes and is the drug of choice for strongyloidiasis. It has CNS side effects and hepatototoxic potential. … (From Smith and Reynard, Textbook of Pharmacology, 1992, p919)

  4. Drug

    Enzalutamide

    go.drugbank.com/drugs/DB08899
    ApprovedInvestigational

    Compared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly.[A252667] … [L40639] It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.

    Products: XTANDI 40 MG, XTANDI ® 40 MG
  5. Drug

    Histrelin

    go.drugbank.com/drugs/DB06788
    ApprovedInvestigationalWithdrawn

    This drug is a synthetic analog of naturally occurring GnRH with a higher potency. … [L41710] GnRH agonists are the first line of treatment for children with central precocious puberty (CPP) due to their capacity to reduce LH levels and the concentration of sex steroids.

  6. Drug

    Pazopanib

    go.drugbank.com/drugs/DB06589
    ApprovedInvestigational

    Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

    Products: VOTRIENT® 200 MG, VOTRIENT® 400 MG
  7. Drug

    Bethanechol

    go.drugbank.com/drugs/DB01019
    Approved

    [A232905,L32539] For example, bethanechol is readily used to treat postoperative or postpartum urinary retention. … An advantage of bethanechol is that in contrast to acetylcholine, bethanechol is not degraded by cholinesterase allowing its effects to be longer-lasting.[L32539]

    Products: Myocholine - Glenwood Tabletten 10 mg, Myocholine - Glenwood Tabletten 25 mg
  8. Drug

    N-alkyl ethylbenzyl dimethyl ammonium (C12-C14)

    go.drugbank.com/drugs/DB11202
    Approved

    and exposure, although the formal mechanism of action of quaternary ammonium compounds like n-alkyl C12-C14 dimethyl ethylbenzyl ammonium chloride is difficult to elucidate. … It is found in sanitizing solutions or soaps as an active ingredient due to its antimicrobial properties.

  9. Drug

    Calcium carbimide

    go.drugbank.com/drugs/DB09116
    ApprovedWithdrawn

    Its effects are similar to the drug disulfiram (Antabuse) in that it interferes with the normal metabolism of alcohol by preventing the breakdown of the metabolic product acetaldehyde. … Calcium carbimide was conceived as an alternative for the treatment of alcoholism with a reduced side effect profile either when it is consumed accompanied by alcohol or without it.

  10. Drug

    Cefonicid

    go.drugbank.com/drugs/DB01328
    Approved

    A second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis.

    Products: CEFONICID EG